)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Cynata Therapeutics
Cynata Therapeutics (CYP) investor relations material
Cynata Therapeutics Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary30 Apr, 2026
Executive summary
Approaching a transformative period with results from two major efficacy trials: Phase 2 aGvHD (results June 2026) and Phase 3 osteoarthritis (results May 2026).
Cymerus platform positioned as a first-mover in iPSC-derived MSC therapies, with commercial-scale manufacturing and strong IP protection.
Regulatory and commercial landscape for MSC and iPSC-derived therapies has strengthened, with new approvals in major markets.
Financial highlights
Cash balance at 31 March 2026 was $1.6 million.
Net operating cash outflows for the quarter were $2.186 million.
$1.204 million raised via At-the-Market Subscription Agreement with Acuity Capital.
Estimated 0.7 quarters of funding available at quarter end.
Outlook and guidance
Positive clinical trial outcomes could drive regulatory progression, commercial validation, and expanded indications.
Capital raising underway to support ongoing operations.
Investor webinar scheduled for May 2026 to discuss upcoming milestones.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cynata Therapeutics
- Major clinical trial results expected by H1 2026, supported by robust cash reserves.CYP
Q3 2025 TU7 Jun 2026 - Pivotal clinical trial results in Q2 CY 2026 could transform commercial prospects.CYPQ2 2026 TU7 Jun 2026
- Three major clinical trial readouts and strong cash runway expected by mid-2026.CYPQ4 2025 TU7 Jun 2026
- CYP-006TK showed strong safety and efficacy in DFU, with robust financial support secured.CYPStudy update6 Jun 2026
- Strong DFU results and cash position support major clinical milestones into 2026.CYPQ2 2025 TU6 Jun 2026
- Pivotal clinical results and strong cash runway set stage for major commercial opportunities.CYPQ1 2026 TU4 Jun 2026
- Advancing clinical pipeline and scalable MSC technology set up multiple near-term catalysts.CYPAGM 2024 presentation4 Jun 2026
- Scalable iPSC-derived MSC platform advances toward major clinical and commercial milestones.CYPInvestor presentation4 Jun 2026
- Scalable Cymerus™ MSC platform drives late-stage clinical pipeline and near-term catalysts.CYPAGM 2025 presentation4 Jun 2026
- Scalable Cymerus™ MSC platform drives late-stage trials and commercial potential in major diseases.CYPInvestor presentation4 Jun 2026
Next Cynata Therapeutics earnings date
H2 202628 Aug, 2026
Cynata Therapeutics
Next Cynata Therapeutics earnings date
H2 202628 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage